Style | Citing Format |
---|---|
MLA | Gharagozloo M, et al.. "Silymarin Inhibits Cell Cycle Progression and Mtor Activity in Activated Human T Cells: Therapeutic Implications for Autoimmune Diseases." Basic and Clinical Pharmacology and Toxicology, vol. 112, no. 4, 2013, pp. 251-256. |
APA | Gharagozloo M, Javid EN, Rezaei A, Mousavizadeh K (2013). Silymarin Inhibits Cell Cycle Progression and Mtor Activity in Activated Human T Cells: Therapeutic Implications for Autoimmune Diseases. Basic and Clinical Pharmacology and Toxicology, 112(4), 251-256. |
Chicago | Gharagozloo M, Javid EN, Rezaei A, Mousavizadeh K. "Silymarin Inhibits Cell Cycle Progression and Mtor Activity in Activated Human T Cells: Therapeutic Implications for Autoimmune Diseases." Basic and Clinical Pharmacology and Toxicology 112, no. 4 (2013): 251-256. |
Harvard | Gharagozloo M et al. (2013) 'Silymarin Inhibits Cell Cycle Progression and Mtor Activity in Activated Human T Cells: Therapeutic Implications for Autoimmune Diseases', Basic and Clinical Pharmacology and Toxicology, 112(4), pp. 251-256. |
Vancouver | Gharagozloo M, Javid EN, Rezaei A, Mousavizadeh K. Silymarin Inhibits Cell Cycle Progression and Mtor Activity in Activated Human T Cells: Therapeutic Implications for Autoimmune Diseases. Basic and Clinical Pharmacology and Toxicology. 2013;112(4):251-256. |
BibTex | @article{ author = {Gharagozloo M and Javid EN and Rezaei A and Mousavizadeh K}, title = {Silymarin Inhibits Cell Cycle Progression and Mtor Activity in Activated Human T Cells: Therapeutic Implications for Autoimmune Diseases}, journal = {Basic and Clinical Pharmacology and Toxicology}, volume = {112}, number = {4}, pages = {251-256}, year = {2013} } |
RIS | TY - JOUR AU - Gharagozloo M AU - Javid EN AU - Rezaei A AU - Mousavizadeh K TI - Silymarin Inhibits Cell Cycle Progression and Mtor Activity in Activated Human T Cells: Therapeutic Implications for Autoimmune Diseases JO - Basic and Clinical Pharmacology and Toxicology VL - 112 IS - 4 SP - 251 EP - 256 PY - 2013 ER - |